Bacterial Antimicrobial Metal Ion Resistance
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Influence of Additives and Storage Temperature on Physicochemical and Microbiological Properties of Eye Drops Containing Cefazolin
Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 63 No. 3 pp. 225ñ234, 2006 ISSN 0001-6837 Polish Pharmaceutical Society PHARMACEUTICAL TECHNOLOGY INFLUENCE OF ADDITIVES AND STORAGE TEMPERATURE ON PHYSICOCHEMICAL AND MICROBIOLOGICAL PROPERTIES OF EYE DROPS CONTAINING CEFAZOLIN. ANNA KODYM 1, TOMASZ ZAWISZA 2, KAMILA BUèKA 2 and HELENA KUKU£A 3 1 Department of Drug Form Technology, Nicolaus Copernicus University Collegium Medicum in Bydgoszcz, 2 Department of Drug Form Technology, 3 Department of Pharmaceutical Bacteriology; K. Marcinkowski University of Medical Sciences in PoznaÒ Abstract: The purpose of the studies was to choose additives for eye drops containing cefazolin and the assess- ment of the influence of used additives and the storage temperature on the physicochemical properties and the stability of the eye drops. The drops were 1% sterile solutions of cefazolin in citrate buffer of pH 6.15-6.20. The drops were preserved with 0.002% thiomersal or 0.001% phenylmercuric borate mixed with 0.4% β- phenylethyl alcohol. Viscosity of the eye drops was increased using polyvinyl alcohol (PVAL). The pharma- ceutical compatibility test of selected additives with cefazolin showed the pharmaceutical interaction of 1% solution of cefazolin with higher than 0.003% concentration of thiomersal, 0.005% benzalkonium chloride and 0.01% chlorhexidine diacetate. The drops, protected from light, were stored at the temperature of 4∞C and 20∞C. As the criteria of the qualitative assessment of freshly prepared drops and during their storage, the following properties were considered: organoleptic analysis, sterility, pH, osmotic pressure, density, viscosity, antimicro- bial activity of cefazolin and preservation efficiency of thiomersal and phenylmercuric borate in the eye drops. -
Selling Mercury Cosmetics and Pharmaceuticals (W-Hw4-22)
www.pca.state.mn.us Selling mercury cosmetics and pharmaceuticals Mercury-containing skin lightening creams, lotions, soaps, ointments, lozenges, pharmaceuticals and antiseptics Mercury is a toxic element that was historically used in some cosmetic, pharmaceutical, and antiseptic products due to its unique properties and is now being phased out of most uses. The offer, sale, or distribution of mercury-containing products is regulated in Minnesota by the Minnesota Pollution Control Agency (MPCA). Anyone offering a mercury-containing product for sale or donation in Minnesota is subject to these requirements, whether a private citizen, collector, non-profit organization, or business. Offers and sales through any method are regulated, whether in a store or shop, classified advertisement, flea market, or online. If a mercury-containing product is located in Minnesota, it is regulated, regardless of where a purchaser is located. Note: This fact sheet discusses the requirements and restrictions of the MPCA. Cosmetics and pharmaceuticals may also be regulated for sale whether they contain mercury or not by other state or federal agencies, including the Minnesota Board of Pharmacy and the U.S. Food & Drug Administration. See More information on page 2. What are the risks of using mercury-containing products? Use of mercury-containing products can damage the brain, kidneys, and liver. Children and pregnant women are at increased risk. For more information about the risks of mercury exposure, visit the Minnesota Department of Health. See More information on the page 2. If you believe you have been exposed to a mercury-containing product, contact your health care provider or the Minnesota Poison Control Center at 1-800-222-1222. -
Aldrich Organometallic, Inorganic, Silanes, Boranes, and Deuterated Compounds
Aldrich Organometallic, Inorganic, Silanes, Boranes, and Deuterated Compounds Library Listing – 1,523 spectra Subset of Aldrich FT-IR Library related to organometallic, inorganic, boron and deueterium compounds. The Aldrich Material-Specific FT-IR Library collection represents a wide variety of the Aldrich Handbook of Fine Chemicals' most common chemicals divided by similar functional groups. These spectra were assembled from the Aldrich Collections of FT-IR Spectra Editions I or II, and the data has been carefully examined and processed by Thermo Fisher Scientific. Aldrich Organometallic, Inorganic, Silanes, Boranes, and Deuterated Compounds Index Compound Name Index Compound Name 1066 ((R)-(+)-2,2'- 1193 (1,2- BIS(DIPHENYLPHOSPHINO)-1,1'- BIS(DIPHENYLPHOSPHINO)ETHAN BINAPH)(1,5-CYCLOOCTADIENE) E)TUNGSTEN TETRACARBONYL, 1068 ((R)-(+)-2,2'- 97% BIS(DIPHENYLPHOSPHINO)-1,1'- 1062 (1,3- BINAPHTHYL)PALLADIUM(II) CH BIS(DIPHENYLPHOSPHINO)PROPA 1067 ((S)-(-)-2,2'- NE)DICHLORONICKEL(II) BIS(DIPHENYLPHOSPHINO)-1,1'- 598 (1,3-DIOXAN-2- BINAPH)(1,5-CYCLOOCTADIENE) YLETHYNYL)TRIMETHYLSILANE, 1140 (+)-(S)-1-((R)-2- 96% (DIPHENYLPHOSPHINO)FERROCE 1063 (1,4- NYL)ETHYL METHYL ETHER, 98 BIS(DIPHENYLPHOSPHINO)BUTAN 1146 (+)-(S)-N,N-DIMETHYL-1-((R)-1',2- E)(1,5- BIS(DI- CYCLOOCTADIENE)RHODIUM(I) PHENYLPHOSPHINO)FERROCENY TET L)E 951 (1,5-CYCLOOCTADIENE)(2,4- 1142 (+)-(S)-N,N-DIMETHYL-1-((R)-2- PENTANEDIONATO)RHODIUM(I), (DIPHENYLPHOSPHINO)FERROCE 99% NYL)ETHYLAMIN 1033 (1,5- 407 (+)-3',5'-O-(1,1,3,3- CYCLOOCTADIENE)BIS(METHYLD TETRAISOPROPYL-1,3- IPHENYLPHOSPHINE)IRIDIUM(I) -
(12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun. -
Meeting Materials)
California State Board of Pharmacy BUSINESS, CONSUMER SERVICES AND HOUSING AGENCY 1625 N. Market Blvd, N219, Sacramento, CA 95834 DEPARTMENT OF CONSUMER AFFAIRS Phone: (916) 574-7900 GOVERNOR EDMUND G. BROWN JR. Fax: (916) 574-8618 www.pharmacy.ca.gov ENFORCEMENT AND COMPOUNDING COMMITTEE REPORT April 18, 2017 Amy Gutierrez, PharmD, Licensee Member, Chair Allen Schaad, Licensee Member, Vice Chair Greg Lippe, Public Member Stan Weisser, Licensee Member Valerie Muñoz, Public Member Ricardo Sanchez, Public Member I. Call to Order, Establishment of Quorum, and General Announcements II. Public Comments on Items Not on the Agenda/Agenda Items for Future Meetings Note: The board may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether to place the matter on the agenda of a future meeting. [Government Code sections 11125, 11125.7(a)] III. Enforcement Matters a. University of California, San Diego’s Pilot Program to Permit Patients to Access Medications from an Automated Drug Delivery System Not Immediately Adjacent to the Pharmacy Background At the April 2015 Board Meeting, the board approved an 18-month pilot study under the auspices of the University of California, San Diego (UCSD) School of Pharmacy involving use of an automated drug delivery system (ADDS) for prescription medication from which staff of Sharp Hospital in San Diego and their families, who opted in, could pick up their outpatient medications. Consultation would be provided via telephone before medication could be dispensed to a patient for first time fills. Since that time the committee has received quarterly updates on the study, including usage of the system. -
Survey of Mercury and Mercury Compounds
Survey of mercury and mercury compounds Part of the LOUS-review Environmental Project No. 1544, 2014 Title: Authors and contributors: Survey of mercury and mercury compounds Jakob Maag Jesper Kjølholt Sonja Hagen Mikkelsen Christian Nyander Jeppesen Anna Juliana Clausen and Mie Ostenfeldt COWI A/S, Denmark Published by: The Danish Environmental Protection Agency Strandgade 29 1401 Copenhagen K Denmark www.mst.dk/english Year: ISBN no. 2014 978-87-93026-98-8 Disclaimer: When the occasion arises, the Danish Environmental Protection Agency will publish reports and papers concerning research and development projects within the environmental sector, financed by study grants provided by the Danish Environmental Protection Agency. It should be noted that such publications do not necessarily reflect the position or opinion of the Danish Environmental Protection Agency. However, publication does indicate that, in the opinion of the Danish Environmental Protection Agency, the content represents an important contribution to the debate surrounding Danish environmental policy. While the information provided in this report is believed to be accurate, the Danish Environmental Protection Agency disclaims any responsibility for possible inaccuracies or omissions and consequences that may flow from them. Neither the Danish Environmental Protection Agency nor COWI or any individual involved in the preparation of this publication shall be liable for any injury, loss, damage or prejudice of any kind that may be caused by persons who have acted based on their understanding of the information contained in this publication. Sources must be acknowledged. 2 Survey of mercury and mercury compounds Contents Preface ...................................................................................................................... 5 Summary and conclusions ......................................................................................... 7 Sammenfatning og konklusion ................................................................................ 14 1. -
Zinc Complexes with Nitrogen Donor Ligands As Anticancer Agents
molecules Review Zinc Complexes with Nitrogen Donor Ligands as Anticancer Agents Marina Porchia 1,* , Maura Pellei 2,* , Fabio Del Bello 3 and Carlo Santini 2 1 ICMATE-C.N.R., Corso Stati Uniti 4, 35127 Padova, Italy 2 Chemistry Division, School of Science and Technology, University of Camerino, via S. Agostino 1, 62032 Camerino, Italy; [email protected] 3 Medicinal Chemistry Unit, School of Pharmacy, University of Camerino, Via S. Agostino 1, 62032 Camerino, Italy; [email protected] * Correspondence: [email protected] (M.P.); [email protected] (M.P.) Academic Editor: Kogularamanan Suntharalingam Received: 7 November 2020; Accepted: 7 December 2020; Published: 9 December 2020 Abstract: The search for anticancer metal-based drugs alternative to platinum derivatives could not exclude zinc derivatives due to the importance of this metal for the correct functioning of the human body. Zinc, the second most abundant trace element in the human body, is one of the most important micro-elements essential for human physiology. Its ubiquity in thousands of proteins and enzymes is related to its chemical features, in particular its lack of redox activity and its ability to support different coordination geometries and to promote fast ligands exchange. Analogously to other trace elements, the impairment of its homeostasis can lead to various diseases and in some cases can be also related to cancer development. However, in addition to its physiological role, zinc can have beneficial therapeutic and preventive effects on infectious diseases and, compared to other metal-based drugs, Zn(II) complexes generally exert lower toxicity and offer few side effects. -
United States Patent (19) 11 Patent Number: 5,753,634 Ebetino Et Al
USOO5753634A United States Patent (19) 11 Patent Number: 5,753,634 Ebetino et al. 45 Date of Patent: May 19, 1998 54 QUATERNARY NITROGEN CONTAINING 4.011777 10/1990 Germany. PHOSPHONATE COMPOUNDS, WO 90/12017 10/1990 WIPO PHARMACEUTICAL COMPOSTIONS, AND WO 91/10646 7/1991 WIPO. METHODS FOR TREATING ABNORMAL Primary Examiner-Amelia Owens CALCUMAND PHOSPHATE METABOLISM Attorney, Agent, or Firm-Richard A. Hake; Karen F. Clark; William J. Winter 75 Inventors: Frank Hallock Ebetino; Marion David Francis, both of Cincinnati, 57 ABSTRACT Ohio; Susan Mary Kaas, Sherburne, Disclosed are quaternary nitrogen-containing, saturated or N.Y. unsaturated monocyclic and bicyclic ring-containing bis 73 Assignee: The Procter & Gamble Company, phosphonate compounds, and pharmaceutically-acceptable Cincinnati, Ohio salts and esters thereof. These compounds, which are useful for treating or preventing disorders of calcium and phos 21) Appl. No.: 52,694 phate metabolism, have the following general structure: 22) Filed: Apr. 30, 1993 (R), (CR2), (CR,): NY R Related U.S. Application Data 63 Continuation-in-part of Ser. No. 891,487, May 29, 1992, abandoned. 51 Int. Cl. ... A61K 31/675; A61K 31/66 52) U.S. Cl. ............................ 514/81: 514/91; 514/109: wherein 546/23: 548/111; 562/21 (a) each X and Y are independently selected from nil, O, 58 Field of Search ............................... 546/23: 514/80, S, NR' and N*(R); if no R' is N'(R), then at least 514/82, 91, 109; 548/111; 562/21 one of X or Y must be N(R); References Cited (b) m and n and m+n are integers from 0 to 5; p and q and 56 p+q are integers from 0 to 3; U.S. -
WO 2018/069805 A2 19 April 2018 (19.04.2018) W !P O PCT
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/069805 A2 19 April 2018 (19.04.2018) W !P O PCT (51) International Patent Classification: (84) Designated States (unless otherwise indicated, for every A61K 9/08 (2006.01) kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (21) International Application Number: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, PCT/IB20 17/056204 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (22) International Filing Date: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 07 October 2017 (07.10.2017) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (25) Filing Language: English KM, ML, MR, NE, SN, TD, TG). (26) Publication Langi English Published: (30) Priority Data: — without international search report and to be republished 201621034602 10 October 2016 (10.10.2016) IN upon receipt of that report (Rule 48.2(g)) (71) Applicant: FTF PHARMA PRIVATE LIMITED [IN/IN]; Plot No. 183+23 1, Above Hyundai Service Centre, Navapura Char Rasta, NH 8A, Ahmedabad-Rajkot High way, Taluka-Sanand, Ahmedabad-382 210, Ahmedabad 382 210 (IN). (72) Inventors: PATEL, Vijay; B-40, Pulin Society Part 3,Near Gayatri School, BethakNaroda, Ahmedabad-382330 Gu jarat, Ahmedabad 382330 (IN). MEHTA, Sandip; D-74, New Jash Park Society, Isanpur, Ahmedabad-382443 Gu jarat, Ahmedabad 382443 (IN). -
Tepzz 459659B T
(19) TZZ _T (11) EP 2 459 659 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: C09D 7/00 (2006.01) C09D 7/14 (2006.01) of the grant of the patent: C09D 5/16 (2006.01) 17.07.2013 Bulletin 2013/29 (86) International application number: (21) Application number: 10737728.5 PCT/US2010/043382 (22) Date of filing: 27.07.2010 (87) International publication number: WO 2011/017097 (10.02.2011 Gazette 2011/06) (54) REMOVABLEANTIMICROBIAL COATING COMPOSITIONS CONTAINING CATIONIC RHEOLOGY AGENT AND METHODS OF USE ABLÖSBARE ANTIMIKROBIELLE BESCHICHTUNGSZUSAMMENSETZUNGEN MIT KATIONISCHEM RHEOLOGISCHEM ADDITIV UND ANWENDUNGSVERFAHREN COMPOSITIONS DE REVÊTEMENT ANTIMICROBIENNES, APTES À ÊTRE RETIRÉES, CONTENANT UN AGENT DE RHÉOLOGIE CATIONIQUE, ET PROCÉDÉS D’UTILISATION (84) Designated Contracting States: (74) Representative: Dannenberger, Oliver Andre et al AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Abitz & Partner GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Patentanwälte PL PT RO SE SI SK SM TR Postfach 86 01 09 81628 München (DE) (30) Priority: 27.07.2009 US 228707 P 27.07.2009 US 228711 P (56) References cited: 27.07.2009 US 228715 P WO-A2-2007/100653 WO-A2-2007/100654 27.07.2009 US 228723 P 26.07.2010 US 843120 • Akzo Nobel Surface Chemistry: "Thickening with polymers"[Online] 1 January 2010 (2010-01-01), (43) Date of publication of application: XP002609717 Akzo Nobel Technical Information 06.06.2012 Bulletin 2012/23 Retrieved from the Internet: URL:http: //www.akzonobel.com/surface/syste m/images/ (73) Proprietor: E. -
PHENYLMERCURIC BORATE Phenylhydrargyri Boras PHENYLMERCURIC NITRATE Phenylhydrargyri Nitras
Phenylmercuric borate EUROPEAN PHARMACOPOEIA 7.0 Second identification: B, C. IDENTIFICATION A. Infrared absorption spectrophotometry (2.2.24). A. Infrared absorption spectrophotometry (2.2.24). Comparison: Ph. Eur. reference spectrum of Preparation:discs. phenylmercuric acetate. Comparison: Ph. Eur. reference spectrum of B. To 5 mL of solution S (see Tests) add 5 mL of water R and phenylmercuric borate. 0.1 mL of sodium sulfide solution R. A white precipitate is B. To 2 mL of solution S (see Tests) add 8 mL of water R and formed that darkens slowly on heating. 0.1 mL of sodium sulfide solution R. A white precipitate is C. To 10 mL of solution S add 2 mL of potassium iodide formed that darkens slowly on heating. solution R and shake vigorously. Filter. The filtrate gives C. Dissolve about 20 mg in 2 mL of methanol R.Thesolution reaction (b) of acetates (2.3.1). is clear and colourless. Ignite; the solution burns with a green-edged flame. TESTS Solution S. Dissolve 0.250 g in 40 mL of water R by heating to TESTS boiling. Allow to cool and dilute to 50 mL with water R. Prepare Solution S. Dissolve 0.25 g by sprinkling it on the surface of the solution immediately before use. 25 mL of boiling water R, cool and dilute to 25 mL with water R. Appearance of solution. Solution S is not more opalescent Appearance of solution. Solution S is clear (2.2.1)and than reference suspension II (2.2.1)andiscolourless(2.2.2, colourless (2.2.2, Method II). -
An Overview on Ligands of Therapeutically Interest
Pharmacy & Pharmacology International Journal Review Article Open Access An overview on ligands of therapeutically interest Abstract Volume 6 Issue 3 - 2018 The principles governing metal-ligand complex stability and specificity depend on the 1 2 properties of both the metal and the chelating agent. The exploration of coordination Julia Martín, Miguel Ropero Alés, Agustin G 2 chemistry offers the real prospects of providing new understanding of intractable diseases Asuero and of devising novel therapeutics and diagnosis agents. Refinement in the approach to 1Department of Analytical Chemistry, Escuela Politécnica chelator design has come with a more subtle understanding of binding kinetics, catalytic Superior, University of Seville, Spain mechanisms and donor interactions. Ligands that effectively bind metal ions and also include 2Department of Analytical Chemistry, Faculty of Pharmacy, specific features to enhance targeting, reporting, and overall efficacy are driving innovation University of Seville, Spain in areas of disease, diagnosis and therapy. In this contribution the topics of bioinorganic medicinal chemistry, chelating agents in the treatment of metallic ion overload in the body, Correspondence: Julia Martín, Department of Analytical and expanding the notion of chelating agent in medicine are successively dealt with, paying Chemistry, Escuela Politécnica Superior, University of Seville. C/ then attention to platinum, gold, iron, copper and aluminium ion metal complexes having Virgen de África, 7, E–41011 Seville, Spain, Tel +34-9-5455-6250, medicinal interest. A tabular summary containing selected applications of ligands and Email [email protected] complexes of therapeutic interest is also shown to including the most relevant and current Received: March 26, 2018 | Published: May 30 2018 bibliography.